PREDICTIVE ONCOLOGY INC (POAI)
US74039M3097 - Common Stock
In today's session, these stocks are experiencing unusual volume.
Unusual volume stocks in Tuesday's session
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates RHE, FUBO, POAI on Behalf of Shareholders
Renovaro Issues Shareholder Letter and Provides Corporate Update
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SSY, FUBO, RHE, POAI on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
These stocks are moving in today's session
Which stocks are experiencing notable movement on Monday?
Renovaro to Acquire Predictive Oncology in All-Stock Transaction
Predictive Oncology Announces Agreement to be Acquired by Renovaro
Predictive Oncology Announces Agreement to be Acquired by Renovaro
- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer...
Predictive Oncology Announces Progress in Ongoing Evaluation of Strategic Alternatives
Predictive Oncology Announces Progress in Ongoing Evaluation of Strategic Alternatives
PITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced progress in...
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update
Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update
Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value...
Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, is scheduled...
Predictive Oncology Study Demonstrates Long-Term Stability and Viability of Proprietary Biobank of Primary Tumor Specimens for Pharmaceutical Drug Discovery
InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Q2 2024 Financial Results, Provides Business Update
Predictive Oncology (NASDAQ: POAI) today announced its financial and operating results for the second quarter ended June 30, 2024, and provided a corporate update. The company reported a net loss of approximately $3.2 million on total revenue of approximately $0.3 million for the quarter. In addition, it concluded Q2 2024 with $5.3 million of cash […]
Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update
Company to host investor call and webcast today, August 14th, at 8:30am EDT
Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update
Company to host investor call and webcast today, August 14th, at 8:30am EDT...
POAI Stock Earnings: Predictive Oncology Reported Results for Q2 2024
Predictive Oncology just reported results for the second quarter of 2024.
POAI Stock Earnings: Predictive Oncology Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Predictive Oncology (NASDAQ:POAI) just reported results for the second quarter ...
Predictive Oncology Expands the Application of its Live-Cell Tumor Platform to De-Risk Drug Discovery and Accelerate Pipeline Development
Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
Management to host conference call and webcast at 8:30am ET
Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024
Management to host conference call and webcast at 8:30am ET...
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today...
Why Is Predictive Oncology (POAI) Stock Up 70% Today?
Predictive Oncology’s AI-driven platform demonstrated predictive utility in oncology, thereby providing credibility to POAI stock.
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results
Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology Biomarker discovery...
7 F-Rated Growth Stocks to Avoid Right Now: June 2024
A good rating for growth in the Portfolio Grader doesn't tell the full picture. These are all growth stocks to avoid now.
Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for...